Actinium-225 macropa pelgifatamab - Bayer
Alternative Names: 225-Ac-pelgifatamab; 225Ac-Pelgifatamab; 225AC- macropa pelgifatamab; 225Ac-pelgi; 225Actinium macropa pelgifatamab; AC-225 macropa pelgifatamab; BAY-3546828; PSMA TAC -BayerLatest Information Update: 31 Mar 2025
At a glance
- Originator Bayer
- Class Antibodies; Antineoplastics; Immunoconjugates; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 20 Sep 2023 Phase-I clinical trials in Prostate cancer (Hormone refractory, Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom, Netherlands, Finland (IV) (NCT06052306) (Bayer pipeline, March 2025)